<DOC>
	<DOC>NCT00649584</DOC>
	<brief_summary>This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.</brief_summary>
	<brief_title>A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Histologically confirmed CD30positive hematologic malignancy. Patients with HL must have failed systemic chemotherapy. Patients with other CD30positive malignancies (including ALCL) must be beyond first remission or refractory to front line chemotherapy. Patients must have measurable disease of at least 1.5 cm as documented by radiographic technique. Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible). History of allogeneic stem cell transplant. Patients who have had previous treatment with any antiCD30 antibody.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens, CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
</DOC>